{"organizations": [], "uuid": "ba94b8212545ec5998b1861179b1bf55d0c6da21", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/10/pr-newswire-gbt-reports-first-quarter-2018-results.html", "country": "US", "domain_rank": 767, "title": "GBT Reports First Quarter 2018 Results", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.328, "site_type": "news", "published": "2018-05-11T02:54:00.000+03:00", "replies_count": 0, "uuid": "ba94b8212545ec5998b1861179b1bf55d0c6da21"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/10/pr-newswire-gbt-reports-first-quarter-2018-results.html", "ord_in_thread": 0, "title": "GBT Reports First Quarter 2018 Results", "locations": [], "entities": {"persons": [{"name": "cresemba", "sentiment": "none"}, {"name": "halaven", "sentiment": "none"}], "locations": [{"name": "uruguay", "sentiment": "none"}, {"name": "montevideo", "sentiment": "none"}, {"name": "abraxane", "sentiment": "none"}, {"name": "brazil", "sentiment": "none"}, {"name": "mexico", "sentiment": "none"}, {"name": "latin america", "sentiment": "none"}], "organizations": [{"name": "gbt", "sentiment": "negative"}, {"name": "biotoscana investments s.a.", "sentiment": "negative"}, {"name": "ebitda", "sentiment": "none"}, {"name": "gilead", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "MONTEVIDEO, Uruguay, Biotoscana Investments S.A. (B3: GBIO33), a biopharmaceutical group that operates in Latin America, announced today its results for the 1Q18.\nHIGHLIGHTS\nGross revenues for 1Q18 grew 10% in constant currency, marking BRL 927M LTM.\nNet revenues for 1Q18 increased by 9% in constant currency, marking BRL820M LTM. 1Q18 grew 12% pro-forma in constant currency (including bids for which we got a purchase order in 1Q18 but we expect to delivery in 2Q18).\nGross profit up 18% in 1Q18, in constant currency. Gross margin of 56% (up ~351bps from 1Q17), continuing the improvement trend of prior quarters.\nAdjusted EBITDA increased by 20% in constant currency vs. 1Q17. Adjusted EBITDA margin came to 25% in 1Q18, improving 172bps vs. 1Q17, marking BRL 203M LTM compared to BRL187M in 1Q17 LTM.\nAdjusted net income up 41% from 1Q17, reaching BRL 22M in 1Q18.\nHalaven and Abraxane off to a strong start. Lenvima launching ahead of schedule and improving clinical profile. Cresemba attained orphan status in Brazil and Mexico.\nExtended partnership with Gilead into the Andean region , with revenues starting in 2Q18.\nContacts:\nMelissa Angelini\nir@grupobiotoscana.com\n+55-11-5090-5927\n releases/gbt-reports-first-quarter-2018-results-300646819.html\nSOURCE Grupo Biotoscana", "external_links": ["http://www.prnewswire.com/news-releases/gbt-reports-first-quarter-2018-results-300646819.html"], "published": "2018-05-11T02:54:00.000+03:00", "crawled": "2018-05-11T04:29:53.000+03:00", "highlightTitle": ""}